Chemical pollutant linked to risk of cancer in males
the ONA take:
According to new findings published in the journal Science of the Total Environment, researchers from the University of Granada in Granada, Spain, have found that exposure to a chemical pollutant known as PCB-153 is positively linked to the risk of cancer in males. This agent can still be found in some fat-rich foods, particularly large, fat-rich fish.
For the study, researchers analyzed the accumulated levels of various pollutants in the body fat of 268 adults and identified those who developed cancer over a 9-year period.
Results showed that the accumulated exposure of PCB-153 was positively associated with the risk of cancer among men.
PCB-153 is part of a group of chemicals widely used in various types of industrial equipment. Because of its high resistance to degradation, the researchers suggest that fat food is the main source of exposure to the chemical pollutant. A fat-rich diet may be the cause of high PCB levels.
The researchers also hypothesize that the pollutant could interact with hormone receptors, produce free radicals, or alter DNA, thus causing cancer.
Exposure to a chemical pollutant known as PCB-153 is positively linked to the risk of cancer in males.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|